Preparation and characterization of amorphous amphotericin B nanoparticles for oral administration through liquid antisolvent precipitation

European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
Yuangang ZuKunlun Wang

Abstract

We prepared amphotericin B (AmB) nanoparticles through liquid antisolvent precipitation (LAP) and by freeze-drying to improve the solubility of AmB for oral administration. The LAP was optimized through a single-factor experiment. We determined the effects of surfactants and their concentration, the stirring time, the precipitation temperature, the stirring intensity, the drug concentration and the volume ratio of antisolvent to solvent on the mean particle size (MPS) of the AmB nanoparticles. Increased stirring intensity and precipitation time favored AmB nanoparticles with smaller MPS, but precipitation times exceeding 30 min did not further reduce the MPS. Increased Tween-80 concentration and the drug concentration decreased the MPS of the AmB nanoparticles. Increased precipitation temperature and antisolvent to solvent volume ratio initially decreased the MPS of the AmB nanoparticles, which increased thereafter. Optimum conditions produced AmB nanoparticles with an MPS of 135.1 nm. The AmB nanoparticles were characterized through scanning electron microscopy (SEM), mass spectrometry (MS), Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), differential scanning calorimetry (DSC), thermal gravimetric ana...Continue Reading

References

Mar 5, 2003·International Journal of Pharmaceutics·O KayserS L Croft
Feb 14, 2006·International Journal of Pharmaceutics·P KocbekJ Kristl
May 19, 2006·International Journal of Antimicrobial Agents·Michael Kleinberg
Oct 21, 2006·International Journal of Pharmaceutics·Herbert ChiouJimmy Yun
May 19, 2009·International Journal of Pharmaceutics·Hai-Xia ZhangJian-Feng Chen
Dec 22, 2009·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Niranjan M DeshpandeVikas V Vaidya
Jan 12, 2010·Nanomedicine : Nanotechnology, Biology, and Medicine·Andreas LemkeOliver Kayser
May 25, 2010·International Journal of Pharmaceutics·Wen-Zhen ZhuJian-Feng Chen
Jul 14, 2010·International Journal of Pharmaceutics·Saifuddin SheikhImran Ahmad
Aug 10, 2010·Nanomedicine : Nanotechnology, Biology, and Medicine·Swarnali Das, Preeti K Suresh
Mar 1, 2012·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Fady IbrahimKishor M Wasan
May 30, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·H Van de VenA Ludwig
Mar 19, 2013·Colloids and Surfaces. B, Biointerfaces·Claudia SalernoCarlos Bregni

❮ Previous
Next ❯

Citations

Aug 11, 2015·International Journal of Pharmaceutics·Ana C Moreno-RodríguezSantiago Torrado-Santiago
Sep 1, 2015·International Journal of Pharmaceutics·Claudia Luengo-AlonsoPaolo Caliceti
Jan 13, 2015·Materials Science & Engineering. C, Materials for Biological Applications·Malika Skiba-LahianiMohamed Skiba
Nov 7, 2016·Journal of Pharmaceutical Sciences·Rajan Jog, Diane J Burgess
Feb 16, 2017·Molecular Pharmaceutics·Miriam RolónMaria Auxiliadora Dea-Ayuela
Feb 6, 2017·Drug Delivery·Min LiuZhiwen Yang
Dec 9, 2017·Therapeutic Delivery·Gabriela Daisy HadiwinotoRichard Lakerveld
Mar 3, 2018·Mycopathologia·Daniel Brustolin LudwigRubiana Mara Mainardes
Dec 5, 2019·Applied Biochemistry and Biotechnology·Shiva Sadat Akhavi, Shahram Moradi Dehaghi
May 16, 2018·Antimicrobial Agents and Chemotherapy·Alicia López-SánchezSusana Torrado
Jan 19, 2020·Pharmaceutics·Silvia VociDonato Cosco
May 17, 2021·International Journal of Pharmaceutics·Vivek VermaLuis Padrela
Jul 20, 2021·World Journal of Microbiology & Biotechnology·Ronisha RamamurthyUsha Y Nayak
Oct 6, 2018·Carbohydrate Polymers·Rossana Gabriela Del Jesus Vásquez MarcanoRubiana Mara Mainardes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Central Nervous System Fungal Infections

Central nervous system fungal infections are rare and typically occur in immunocompromised patients, such as those with HIV infection or transplant recipients. Discover the latest research on central nervous system fungal infections here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.